- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01836172
YJP-14 Capsules for the Treatment of Endothelial Dysfunction in Patients With Diabetes Mellitus
Multicenter, Randomized, Double Blind, Placebo-controlled, Phase II Clinical Trial to Evaluate the Safety and Efficacy of YJP-14 Capsules for the Treatment of Endothelial Dysfunction in Patients With Diabetes Mellitus
Studieoversigt
Detaljeret beskrivelse
The primary purpose of this study is to demonstrate superior effect of YJP-14 three doses, 25, 50 and 100 mg t.i.d on endothelial dysfunction in diabetes mellitus indicated as mean change difference of flow-mediated dilation (FMD), compared to placebo group after treatment of 12 weeks.
The secondary purposes of this study are divided into three as follows;
- Clinically significant effect of YJP-14 three doses, 25, 50 and 100 mg t.i.d on endothelial dysfunction in diabetes mellitus indicated as mean change difference of FMD, compared to placebo group after treatment of 8 weeks.
- Clinically significant effect of YJP-14 three doses, 25, 50 and 100 mg t.i.d on insulin resistance in diabetes mellitus indicated as mean change difference of Homeostasis Model Assessment-Insulin Resistance (HOMA-IR), compared to placebo group after treatment of 4, 8 and 12 weeks.
- Clinically significant effect of YJP-14 three doses, 25, 50 and 100 mg t.i.d on mean change difference of blood pressure in diabetes mellitus, compared to placebo group after treatment of 4, 8 and 12 weeks.
The exploratory purposes of this study are divided into two as follows;
- Clinically significant effect of YJP-14 three doses, 25, 50 and 100 mg t.i.d on blood glucose level in diabetes mellitus indicated as mean change difference of HbA1c, compared to placebo group after treatment of 12 weeks.
- Clinically significant effect of YJP-14 three doses, 25, 50 and 100 mg t.i.d on vascular stiffness in diabetes mellitus indicated as mean change difference of blood lipids (LDL, HDL and TG), compared to placebo group after treatment of 12 weeks.
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Seoul, Korea, Republikken, 110-744
- Internal medicine, Seoul National University Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Adult-onset DM (defined as fasting glucose greater than 125 mg/dl or by ongoing treatment with an oral hypoglycemic agent), Endothelial dysfunction: FMD below 6.7%, LDL cholesterol level less than 140 mg/dl, Patients agreed to Informed Consent Form
Exclusion Criteria: (Key exclusion criteria) Uncontrolled arterial hypertension (above 139/90 mmHg) or hypotension (below 80/50 mmHg), Severe diabetic complication: diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic vascular complications
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Placebo komparator: Placebo t.i.d.
|
An 50% ethanolic extract of Lindera obtusiloba stems
Andre navne:
|
Placebo komparator: YJP-14 25 mg t.i.d.
YJP-14 25 mg t.i.d.
YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.
|
An 50% ethanolic extract of Lindera obtusiloba stems
Andre navne:
|
Placebo komparator: YJP-14 50 mg t.i.d.
YJP-14 50 mg t.i.d.
YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.
|
An 50% ethanolic extract of Lindera obtusiloba stems
Andre navne:
|
Placebo komparator: YJP-14 100 mg t.i.d.
YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.
YJP-14 100 mg t.i.d.
|
An 50% ethanolic extract of Lindera obtusiloba stems
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Flow-mediated dilation (FMD)
Tidsramme: 12 weeks
|
12 weeks
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Flow-mediated dilation (FMD) Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) Systolic and Diastolic Blood Pressure
Tidsramme: 8 weeks
|
8 weeks
|
Homeostasis model assessment-insulin resistance (HOMA-IR)
Tidsramme: 4, 8, 12 weeks
|
4, 8, 12 weeks
|
Systolic and Diastolic Blood Pressure
Tidsramme: 4, 8, 12 weeks
|
4, 8, 12 weeks
|
Andre resultatmål
Resultatmål |
Tidsramme |
---|---|
HbA1c Serum lipids (LDL, HDL and TG)
Tidsramme: 12 weeks
|
12 weeks
|
Serum Lipids (LDL, HDL and TG)
Tidsramme: 12 weeks
|
12 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Byung-Hee Oh, M.D., Ph.D., Seoul National University Hospital
Publikationer og nyttige links
Generelle publikationer
- Lee JO, Oak MH, Jung SH, Park DH, Auger C, Kim KR, Lee SW, Schini-Kerth VB. An ethanolic extract of Lindera obtusiloba stems causes NO-mediated endothelium-dependent relaxations in rat aortic rings and prevents angiotensin II-induced hypertension and endothelial dysfunction in rats. Naunyn Schmiedebergs Arch Pharmacol. 2011 Jun;383(6):635-45. doi: 10.1007/s00210-011-0643-9. Epub 2011 May 2.
- Lee JO, Auger C, Park DH, Kang M, Oak MH, Kim KR, Schini-Kerth VB. An ethanolic extract of Lindera obtusiloba stems, YJP-14, improves endothelial dysfunction, metabolic parameters and physical performance in diabetic db/db mice. PLoS One. 2013 Jun 3;8(6):e65227. doi: 10.1371/journal.pone.0065227. Print 2013.
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- HW2012-YJP002
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Diabetisk komplikation
-
Kahramanmaras Sutcu Imam UniversityAfsluttetFedme, sygelig | Perioperativ komplikation | BMD | Laparaskopisk ærmegatrektomi | Fedmekirurgi Dødelighedsscore | Clavien Dindo Surgical Complication Scale
-
Assiut UniversityUkendtom Vitreomacular Interface Abnormalities in Diabetic Retinopathy
Kliniske forsøg med YJP-14
-
PfizerAfsluttet
-
Robert Jones and Agnes Hunt Orthopaedic and District...Smith & Nephew, Inc.Rekruttering
-
PATHAfsluttetEncephalitis, japansk BFilippinerne
-
Jiaxing AnDiCon Biotech Co.,LtdRekruttering
-
SRI InternationalRekrutteringToksicitet;KemiskForenede Stater
-
University of CopenhagenAfsluttet
-
Federal Budgetary Research Institution State Research...AfsluttetKopper | Abekopper | Kokopper | Vaccinia virus infektionDen Russiske Føderation
-
Udo SechtemAfsluttet
-
PATHAfsluttet